Open Nav

EnduRx Pharmaceuticals Inc.

Gaini visibility for EnduRx

  • Date:Wednesday, October 17
  • Time:2:30 PM - 2:45 PM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:EnduRx is advancing a novel, nanoparticle-based, actively-targeting drug delivery system Our focus is hard-to-treat solid tumors. Target of the prototype drug is a ubiquitous protein that is surface-expressed ini nutritionally-deprived tumor tissue, and the prototype molecule transports a cytotoxic payload into and throughout the tumor microenvironment in a matter of minutes, developing therapeutically-effective concentrations. Toxicity during delivery is low as the prodrug is not activated until it is bound to the target cell-surface protein. A $1.75MM grant yielded promising data in mouse models of triple-negative breast cancer and glioblastoma. Our novel MOA, orthogonal to other oncology drugs, offers oncologists a new tool with which to address resistance and escape. We expect the delivery system to present multiple opportunities to transport approved and developmental drugs into tumor microenvironments, presenting a spectrum of opportunities for partnerships.
  • Company (stealth)
  • Company HQ City:San Diego
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:David Loynd
  • Year Founded:20111
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Unnamed prototype for treatment of triple-negative breast cancer
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :Potentially many, specifics not yet defined
  • Additional Information/Comments:This promising drug delivery system is not easily categorized. There are few peptide-based nanoparticle therapeutics approved and CMC issues are challenging (but not insoluble). The company is currently raising a seed round from impact investors and has submitted several grant applications.
  • Previous and Current Investors:NIH-NCI
  • Size of Last Investment Round:$1.75MM
  • Total Amount Raised to Date, In All Rounds:$1.75MM (grant)